ABSTRACT
Herpes zoster is a cluster blister disease that often occurs on the skin of the elderly, immunocompromised individuals and patients with chronic diseases, which is caused by the reactivation of varicella zoster virus dormant in neurons. The persistent pain of herpes zoster tortures patients and is responsible for serious mental and economic burden. With no effective drug treatment for patients, vaccination becomes more important in disease prevention. Now live attenuated vaccine and recombinant protein vaccine with adjuvant are clinically available abroad. Based on the clinical data, recombinant protein vaccine with adjuvant is the preferred one recommended by CDC.In China, many enterprises perform clinical studies on the two vaccines. However, due to the limitation of adjuvant supply, recombinant protein vaccines have not been widely provided. With the global pandemic of COVID-19, mRNA vaccine becomes a hotspot worldwide. Domestic biological enterprises should actively develop new herpes zoster vaccine to fill the vaccine vacancies in China and to enhance market competitiveness. This article briefly reviews the research progress and development of herpes zoster vaccine in various vaccine platforms.
ABSTRACT
In the Chinese city of Wuhan at the end of 2019, an infection by an unknown virus began, which with subsequent studies was called SARS-CoV-2, causing a pandemic that has generated the largest crisis worldwide in recent years, causing a large number of deaths, with multiple systemic manifestations but which has also had clinical pictures at the skin level;recently there have been reports of people who had COVID-19 infections and later had skin manifestations due to herpes virus as a co-infection;the most frequent were herpes simplex type 1-2, varicella zoster, herpes zoster and herpes virus 6-7, generating even more complications in patients. Although the pathogenesis of this association is not entirely clear, it is believed to be secondary to the state of immunosuppression induced by SARS-CoV-2, being important that health personnel are informed about this entity that increases mortality.
ABSTRACT
The infection caused by SARS-CoV-2 may result in a series of skin damages. In addition, some patients report the re-activation of the varicella-zoster virus, which might be related to T cell immune dysfunction caused by SARS-CoV-2 infection. Recently, studies reported herpes zoster occurrence after inoculating the COVID-19 vaccine. At present, the mechanism of interaction between COVID-19, COVID-19 vaccine and herpes zoster remains unclear, and more high-quality studies are required to further define the relationship.
ABSTRACT
Objective: To analyze the characteristics of the associated epidemics in Tongzhou district of Beijing from 2015 to 2020, identify the risk factors and provide scientific basis for the early warning, prevention and control of infectious disease epidemics.
ABSTRACT
Objective: Increased anxiety among individuals following the declaration of the coronavirus disease (COVID-19) pandemic, changes in social life, and dermatological eruptions caused or triggered by the COVID-19 infection have altered the incidence of dermatological diseases. To determine the impact of the pandemic, this study evaluated changes in the frequency, profile, and diagnostic spectrum of dermatology patients during the pandemic compared to the previous year. Materials and Methods: This study compared a 6-month period from March 2020, when the first COVID-19 case was reported in Turkey, to September 2020, with the same period in 2019. Age, sex, diagnosis groups, and diagnoses were recorded and compared with the previous year.
ABSTRACT
Aim: Varicella zoster virus (VZV) is a double stranded DNA virus from herpes virus family. Only infection source is human and it is very contagious. With this case we want to mention about atypical presentation of zona and it should be kept in mind as differential diagnosis for atypically located vesicular lesions. Case: 50 years old healthcare worker female patient presented to emergency service with parestesia and coldness of one leg followed by vesicular lesions. Predisposing factors are chronic disease, immunocompromising disease, age more than 60 but for our patient no predisposing factors observed. The COVID Pandemic has brought with it other additional health problems.
ABSTRACT
Theoretically, the subunit herpes zoster vaccine ShingrixTM could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have made its application economically impracticable. With lipid nanoparticles (LNPs) that were approved by the FDA as vectors for severe acute respiratory syndrome coronavirus 2 vaccines, we designed a series of vaccines efficiently encapsulated with varicella-zoster virus glycoprotein E (VZV-gE) and nucleic acids including polyinosinic-polycytidylic acid (Poly I:C) and the natural phosphodiester CpG oligodeoxynucleotide (CpG ODN), which was approved by the FDA as an immunostimulator in a hepatitis B vaccine. Preclinical trial in mice showed that these LNP vaccines could induce VZV-gE IgG titers more than 16 times those induced by an alum adjuvant, and immunized serum could block in vitro infection completely at a dilution of 1:80, which indicated potential as a varicella vaccine. The magnitude of the cell-mediated immunity induced was generally more than 10 times that induced by the alum adjuvant, indicating potential as a zoster vaccine. These results showed that immunostimulatory nucleic acids together with LNPs have promise as safe and economical varicella and zoster vaccine candidates.